View Cancer Clinical Trials

Cancer Answer Line: 866.223.8100

Cancer Answer Line:

866.223.8100

View Cancer Clinical Trials

RTOG 0538   |   CC707
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
Disease(s)
Lung
Hospital(s)
Fairview
Hillcrest
Independence
Main Campus
Strongsville
Wooster
Phase(s)
Phase 3
Stage(s)
Type(s)
Ancillary
Drug(s)
Cisplatin
Etoposide
Contact Information
Cancer Answer Line

866.223.8100

8:00 am - 4:30 pm, Monday - Friday

Description
  1. To determine whether administering high dose thoracic radiotherapy, 70 Gy (2 Gy once-daily over 7 weeks) or 61.2 Gy (1.8 Gy once-daily for 16 days followed by 1.8 Gy twice daily for 9 days), will improve median and 2 year survival compared with 45 Gy (1.5 Gy twice daily over 3 weeks) in patients with limited stage small cell lung cancer.
Inclusion Criteria
  1. Histologically or cytologically documented small cell lung cancer
  2. Limited stage disease patients, with disease restricted to one hemithorax with regional lymph node metastases, including ipsilateral hilar, ipsilateral and contralateral mediastinal, and ipsilateral supraclavicular lymph nodes.
    • Patients with disease involvement of the contralateral hilar or supraclavicular lymph nodes are not eligible
    • Patients with pleural effusions that are visible on plain chest radiographs, whether cytologically positive or not, are not eligible.
    • Patients with cytologically positive pleural or pericardial fluid, regardless of the appearance on plain x-ray, are not eligible.
  3. Patients must have measurable disease, which includes lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 2cm with conventional techniques or as ≥ 1 cm with spiral CT scan.
  4. No prior radiotherapy or chemotherapy for SCLC.
  5. No prior mediastinal or thoracic radiotherapy
  6. Patients with complete surgical resection of disease are not eligible.
  7. Age ≥ 18 years of age.
  8. ECOG Performance Status 0-2
  9. No patients that are known to be pregnant or nursing
  10. Required Initial Laboratory Values:
    • Granulocytes: ≥ 1,500/µl
    • Platelet Count: ≥ 100,000/µl
    • Total Bilirubin: ≤ 1.5 x ULN
    • AST (SGOT): ≤ 2.0 x ULN
    • Serum Creatine OR: ≤ 1.5 x ULN
    • Calculated Creatine Clearance: ≥ 70ml/min
Exclusion Criteria
Exclusion Criteria Not Available

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2013 Cleveland Clinic. All rights reserved.